NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company’s co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief…


Previous articleAccountability & Transformative Justice in the Psychedelic Space: A Roadmap for Change
Next articleFilament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update